NDA 017284 · Shine
Xenon Xe 133
Xenon Xe-133 · Inhalation · Inhalation Diagnostic Agent
Last checked: Nov 19, 2026Latest source record: Jun 10, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Oct 10, 1974
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
3 Phase 3, 1 recruiting
FAERS reports
13
2 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2026.
INDICATIONS AND USAGE: Inhalation of Xenon Xe 133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- XENON XE 133 · XENON XE-133 10mCi/VIAL · GAS, INHALATION · Prescription
- XENON XE 133 · XENON XE-133 20mCi/VIAL · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Xenon Xe-133" as an intervention, any sponsor and status, largest first.
- A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation ScintigraphyPivotal-lookingTerminated
Cyclomedica Australia PTY LimitedIndustry
NCT03054870 · 226 participants · Start Sep 1, 2017 · Primary completion Sep 18, 2020
Drug: Xe-133; Technegas · For: Lung Structure Determination
Sites: Clearwater, Florida; Jacksonville, Florida; Maywood, Illinois · 9 sites in all
- Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung ResectionPivotal-lookingCompleted
Polarean, Inc.Industry
NCT03417687 · 38 participants · Start Aug 17, 2018 · Primary completion Oct 31, 2019
Drug: 129Xe MRI; 133 Xe scintigraphy · For: Pulmonary Surgical Procedures
Sites: Durham, North Carolina; Cincinnati, Ohio; Charlottesville, Virginia
University of VirginiaAcademic, hospital or other
NCT03331302 · 30 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Hyperpolarized Xenon-129 MRI (Experimental); Radioactive Xenon-133 scintigraphy (Active Comparator) · For: Chronic Obstructive Pulmonary Disease
Sites: Charlottesville, Virginia
- Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary EmbolismPivotal-lookingTerminated
Cyclomedica Australia PTY LimitedIndustry
NCT01458639 · 18 participants · Start Aug 2012 · Primary completion Jun 2015
Drug: Technegas V SPECT imaging; Xenon-133 Ventilation Planar imaging · For: Pulmonary Embolism
Sites: St Louis, Missouri; New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- occupational exposure to product4
- nasal discomfort2
- throat irritation2
- urticaria2
- accidental exposure1
- accidental exposure to product1
- alanine aminotransferase decreased1
- beta 2 microglobulin increased1
- blood alkaline phosphatase increased1
- blood bilirubin decreased1
- blood cholinesterase decreased1
- blood creatine phosphokinase decreased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2024 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Shine
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.